Companies › Verve Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular, Metabolic and endocrine; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VERVE-102 Base-editing technology designed to disrupt PCSK9 gene expression in the liver | PCSK9 | Phase 1 | Heterozygous Familial Hypercholesterolemia | Oct 2027 |
| VERVE-201 Base-editing technology to inactivate ANGPTL3 gene expression in hepatocytes | ANGPTL3 | Phase 1 | Hypercholesterolemia | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06164730 | VERVE-102 | Phase 1 | Heterozygous Familial Hypercholesterolemia | Cardiovascular | Oct 2027 |
| NCT06451770 | VERVE-201 | Phase 1 | Hypercholesterolemia | Metabolic and endocrine | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.